Fibromyalgia

This report summarises what Blossom’s database shows about psychedelics and fibromyalgia, and it is an unusually clean example of a strong idea outrunning its evidence. Fibromyalgia is the prototype of pain that the brain itself amplifies, which makes it one of the most mechanistically appealing targets in the whole field for the notion that psychedelics might reset central pain processing. Yet the actual human evidence is a five-person open-label pilot, a controlled ketamine trial that came up short on durability, and a stack of patient surveys. The rationale is real; the proof is barely begun.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a treatment recommendation. No psychedelic is approved for fibromyalgia, and the studies described are early-stage research. Effective, if modest, treatments exist, exercise, cognitive behavioural therapy, sleep management and several approved medicines, and they are the right starting point. Fibromyalgia is real and often poorly served, but that is a reason to seek good care and, where possible, well-run trials, not to self-experiment with unregulated substances. If you are struggling with pain and low mood, please work with a clinician.

A word on scope and numbers. Blossom tracks only a handful of papers and a modest set of trials here, and many of the trials are still recruiting rather than reporting. The completed, results-bearing clinical evidence in fibromyalgia is very small, effectively one open-label psilocybin pilot and some older ketamine work. Read the counts as a field gearing up, not one that has delivered answers.

Why fibromyalgia fits the theory

The reason this topic is worth taking seriously starts with what fibromyalgia is. It is the clearest clinical example of nociplastic pain, pain generated and amplified by the central nervous system rather than by tissue damage or inflammation. People with fibromyalgia have widespread pain, but also disrupted sleep, profound fatigue, cognitive fog and, very often, depression and anxiety, a whole-system, brain-centred picture. Conventional painkillers, which target peripheral pain and inflammation, work poorly precisely because the problem is not peripheral.

That is what makes psychedelics conceptually interesting here in a way they are not for, say, arthritis. The central hypothesis of psychedelic pain research, that these drugs might alter how the brain processes and amplifies pain, and simultaneously ease the depression and catastrophising that accompany it, maps unusually well onto a condition that is itself fundamentally about central amplification and emotional load. If the theory is right anywhere in chronic pain, fibromyalgia is one of the places it should show up. That is a reason for genuine interest, and also a reason to be especially careful not to let the elegance of the fit substitute for data.

The lead study, in full and honest proportion

The first and most important human study is a 2025 open-label pilot of psilocybin-assisted therapy for fibromyalgia[1]Front Pain Res, psilocybin-assisted therapy for fibromyalgia open-label pilot (2025), from a respected academic collaboration. Participants received two psilocybin doses with preparation and integration therapy. The results, on their own terms, were encouraging: the treatment was safe and well tolerated, with only transient rises in blood pressure and heart rate and some short-lived headaches, and participants reported improvements across many fibromyalgia symptoms. As a demonstration that psilocybin can be given safely to this group and that benefit is plausible, it does its job.

But the proportion matters enormously. The study enrolled five people. It had no control group and no blinding, so there is no way to separate a real drug effect from expectation, the natural ups and downs of fibromyalgia, or the considerable attention and support participants received. In a condition where symptoms fluctuate and where placebo responses are typically large, a five-person open-label result is a starting point, not a finding. The right way to read it is that it justifies the controlled trials now recruiting, including larger, multi-centre and biomarker-based studies, and that those trials, not this pilot, will tell us whether psilocybin treats fibromyalgia.

Ketamine: the mechanism works, the durability does not

Ketamine offers a useful, sobering counterpoint, because it is the one psychedelic-adjacent drug with a longer fibromyalgia track record. Its rationale is excellent: by blocking the NMDA receptor central to pain "wind-up" and sensitisation, it targets the very mechanism thought to drive fibromyalgia, and it does reduce pain acutely. On paper, it should work. In practice, a controlled trial found that a short-term S-ketamine infusion produced no lasting analgesic effect[2]Eur J Pain, no long-term analgesia from short S-ketamine infusion in fibromyalgia RCT (2012).

That result is a warning worth heeding as the psilocybin trials proceed. It shows that hitting the right central mechanism, even convincingly, does not guarantee durable benefit, and that transient relief, which is easy to mistake for success in an open-label or short-term study, can fade completely. Fibromyalgia has a long history of treatments that looked promising on mechanism and disappointed in durability. The ketamine experience is a reminder to judge the coming psilocybin trials on lasting, controlled outcomes rather than on short-term impressions.

The patient community, and weak but real signals

One feature sets fibromyalgia apart from most pages here: a large, organised, self-treating patient community. Surveys of people with fibromyalgia find that many already use psychedelics, often by microdosing, and report benefit[3]J Psychoactive Drugs, psychedelics use among individuals with fibromyalgia survey (2022), and wider survey work suggests perceived analgesic effects of psychedelics across several chronic pain conditions[4]Eur J Pain, analgesic effects of psychedelics on chronic pain survey (2023). There are also vivid individual accounts, such as a case report of long-lasting relief after changa[5]J Psychedelic Studies, long-lasting analgesia from changa case report (2019).

These deserve to be taken seriously as a reason to research, and treated cautiously as evidence. Surveys and case reports are uncontrolled and self-selected; the people who try psychedelics and report back are not a random sample, and those who benefit are more likely to share. They generate a real, testable hypothesis, that low-dose or full-dose psychedelics help fibromyalgia, but they cannot confirm it, and microdosing in particular, popular as it is in this community, has essentially no controlled support for pain. The honest stance respects the patient experience enough to insist on testing it properly.

Reading this honestly

So where does fibromyalgia sit? It is one of the most promising rationales in psychedelic pain research and one of the least proven, an unusually pure case of theory ahead of evidence. The mechanism fits: this is central, brain-amplified pain wrapped in mood and cognitive symptoms, exactly what a central-resetting treatment should suit. The data do not yet match: a five-person open-label pilot, a ketamine trial that confirmed the mechanism but not durability, and a community of patients reporting benefit they have not been able to test. For people living with fibromyalgia, the truthful message is genuinely hopeful and genuinely unfinished: this may prove to be one of the better psychedelic pain indications, the trials that could show it are now under way, and until they report, the proven if modest treatments, exercise, therapy and approved medicines, remain where care should sit, and unregulated self-treatment is not a safe shortcut.